Product Description
Healthpoint was developing hp011-101, a Topical agent for the Management of Stage I-II Pressure Ulcers in Patients With Spinal Cord Injury. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01273428)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Healthpoint
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Injuries/wounds Unspecified|Pressure Ulcer|Spinal Cord Injuries
Phase 1: Dermatitis, Photoallergic|Injuries/wounds Unspecified|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT01433159 | P2 |
Terminated |
Pressure Ulcer|Spinal Cord Injuries |
2013-01-01 |
|
| NCT01273428 | P2 |
Withdrawn |
Pressure Ulcer |
2011-06-01 |
|
| NCT00714519 | P2 |
Withdrawn |
Injuries/wounds Unspecified |
2008-10-01 |
|
| NCT00713349 | P2 |
Completed |
Injuries/wounds Unspecified |
2008-08-01 |